abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

abrdn Life Sciences Investors (NYSE:HQL) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 32,205 shares, an increase of 71.7% from the February 26th total of 18,752 shares. Based on an average trading volume of 133,056 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HQL. World Investment Advisors boosted its position in shares of abrdn Life Sciences Investors by 7.2% in the 4th quarter. World Investment Advisors now owns 99,520 shares of the company’s stock worth $1,670,000 after buying an additional 6,654 shares in the last quarter. Invesco Ltd. purchased a new position in abrdn Life Sciences Investors during the 4th quarter valued at about $275,000. Mercer Global Advisors Inc. ADV purchased a new position in abrdn Life Sciences Investors during the 4th quarter valued at about $177,000. Evolve Private Wealth LLC acquired a new position in abrdn Life Sciences Investors during the fourth quarter worth about $199,000. Finally, Guggenheim Capital LLC lifted its holdings in shares of abrdn Life Sciences Investors by 55.1% in the fourth quarter. Guggenheim Capital LLC now owns 41,067 shares of the company’s stock valued at $689,000 after purchasing an additional 14,582 shares in the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Price Performance

Shares of NYSE:HQL traded down $0.51 during trading on Friday, hitting $16.03. 92,000 shares of the stock were exchanged, compared to its average volume of 125,727. The company has a fifty day moving average price of $16.74 and a two-hundred day moving average price of $16.49. abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $17.80.

abrdn Life Sciences Investors Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Friday, February 20th will be given a dividend of $0.56 per share. The ex-dividend date is Friday, February 20th. This is a positive change from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50. This represents a $2.24 dividend on an annualized basis and a yield of 14.0%.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.